Skip to main content
Premium Trial:

Request an Annual Quote

EpiVax, BioAtla Collaborate on Antibody Screening Technology

NEW YORK (GenomeWeb News) – EpiVax's immunogenicity screening technology will be incorporated into BioAtla's antibody Express Humanization platform under a collaboration announced today.

Providence, RI-based EpiVax has developed in silico tools for the immunogenicity screening of protein therapeutics, immunogenicity mitigation, and T cell-driven vaccine design, while San Diego-based BioAtla's Express Humanization platform "entails synthesizing a combinatorial library of non-human target monoclonal antibodies fused in frame to a validated collection of human frameworks, and screening for binding, function, and expression."

Combining the two companies' technologies, they said, provides a third level clone selection criterion for developing human antibody therapeutics, immunogenicity, thereby expanding the functional selectivity of BioAtla's expression-based humanization process.

Financial and other terms of the deal were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.